Loading data for PAVM — first visit, this takes a few seconds.
PAVmed Inc.
5.28 +0.19 (3.73%)
4.72 +0.00%
- Market Cap
- $37.74M
- Volume
- 66.4K
- Dividend yield
- n/a
- Next earnings date
- Nov 12, 2026
PAVmed Inc. (PAVM) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $33.00K | n/a | +450.00% |
| EPS | -$0.27 | +$0.36 | +82.00% |
Metrics
- Bid
- 3.64
- Market Cap
- 37.7M
- Revenue (ttm)
- 112K
- Net Income (ttm)
- -20.6M
- 0.54
- -17.03
- n/a
- -1.98
- P/B (ttm)
- 0.95
- P/S (ttm)
- 336.97
- Earnings Date
- Nov 12, 2026
- Ask
- 6.59
- Volume
- 66,445
- Avg. Volume (20D)
- 29,122
- Open
- 5.07
- Previous Close
- 5.09
- Day's Range
- 4.90 - 5.38
- 52-Week Range
- 3.85 - 28.44
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About PAVmed Inc.
View profile →PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Industry Medical Devices
Sector Healthcare
IPO Date Jul 27, 2016
Employees 41
Stock Exchange NasdaqCM
Ticker Symbol PAVM
Website https://www.pavmed.com